Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
Clinical trial NCT06015750 · WITHDRAWN
Trial details
- NCT number
- NCT06015750
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-29
- Primary completion
- 2030-03-13
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.